

March 11, 2010
Shionogi & Co., Ltd.
TAKATA SEIYAKU CO., Ltd.

Shionogi and TAKATA SEIYAKU Announce Agreement on Succession of Marketing and Manufacturing Rights

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) and TAKATA SEIYAKU CO., Ltd. (Head Office: Tokyo, Japan; President and Representative Director: Shigeki Takada; hereafter “TAKATA SEIYAKU”) today announced that Shionogi has agreed to assign its marketing and manufacturing rights to TAKATA SEIYAKU regarding 5 products listed as follows on April 1, 2010.

TAKATA SEIYAKU will conduct the marketing and manufacturing in addition to the provision and collection of information of the 5 products after April 1, 2010.

Shionogi will concentrate the sales and marketing activities to the targeted and newly launched products and TAKATA SEIYAKU will dedicate to extend its distribution route by this agreement. Both companies will try to further enhance stable supply to the medical institutions and adequate provision of medical information of these products.

1. Products to succeed:

1. Colchicine 「SHIONOGI」 *
2. Shiosol[®]
3. Dicletamin[®]
4. Blocklin[®]-L
5. Millact[®]

* Colchicine 「SHIONOGI」 will be launched as Colchicine 「TAKATA」 by this agreement.

2. Succession date: April 1, 2010

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596

Sales Planning and Marketing Department

TAKATA SEIYAKU CO., Ltd.

Telephone: +81-48-622-8950

Fax: +81-48-623-3065